Howland Capital Management LLC Acquires 111 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Howland Capital Management LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,965 shares of the company’s stock after buying an additional 111 shares during the quarter. Howland Capital Management LLC’s holdings in IDEXX Laboratories were worth $20,658,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in IDXX. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $37,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Down 0.2 %

IDXX stock opened at $459.78 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The business has a fifty day moving average price of $428.35 and a 200-day moving average price of $453.56. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The stock has a market capitalization of $37.65 billion, a P/E ratio of 43.09, a P/E/G ratio of 3.47 and a beta of 1.37.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Finally, Piper Sandler reiterated a “neutral” rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $524.38.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.